الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Periodontitis can be defined as “An infectious disease resulting in inflammation within the supporting tissues of the teeth, as well as progressive attachment, and bone loss.
Periodontal treatment should result in inflammation elimination, stop periodontal disease progression, enhance esthetics, and produce an environment which is useful to maintain periodontal health.
The first step in the treatment of periodontitis is mechanical debridement, which lead to disturbing the biofilm and reducing the bacterial load. The base of deep pockets of periodontitis in some cases are difficult to access for periodontal instrumentation and hence mechanical methods alone are insufficient. Thus, some residual pockets remain after therapy and periodontal surgeries may be needed to resolve these residual pockets.
Periodontitis is associated with bone resorption classified into Suprabony or infrabony. Infrabony defects are more predictable to success to bone regeneration and to overall reduction in defect depth. So, open flap debridement with adjunctive treatment were recommended.
Platelets concentrates are considered as important reservoirs of various growths factors and cytokines, which play a vital role in inflammation, wound repair, homeostasis, and antimicrobial host.
Injectable platelet rich fibrin (I-PRF) is a type of platelets concentrate which released variable growth factors which aid in healing process. The released growth factors are such as insulin-like growth factor I-II (IGF I-II), platelet-derived growth factor (PDGF), Transforming growth factor-beta (TGFβ-1) and vascular endothelial growth factor (VEGF). I-PRF characterized by the presence of higher concentrations of growth factors and stem cells which can be observed when compared to other formulations of PRF that could facilitate wound healing and bone regeneration.
Statins are types of drugs used in treatment of high cholesterol level by decreasing levels of hydroxy‐methyl‐glutaryl co‐enzyme A reductase that cause reduction of the mevalonate pathway, which has to be included in the production of cholesterol in the liver.
Simvastatin is a type of statin which can also induce angiogenesis by inducing production of vascular‐endothelial growth factor and osteogenesis by inducing production of bone morphogenetic protein‐2 (BMP‐2) and inhibit the activator receptors of nuclear factor κB and its ligand (RANK‐RANKL) which inhibit osteoclasts and can help in decreasing bone resorption.
So, this study was performed to compare between the clinical and radiographic effectiveness of local application of I-PRF and Simvastatin 1.2% gel as an adjunct to open flap debridement in the management of infrabony defects in stage III periodontitis.
Both groups showed significant improvement in clinical parameters, radiographic bone fill after 6 months of follow up, with a percentage change in group I (I-PRF) (53.75%), (47.42%) and (24.03%) and in group II (SMV) (50.48%), (48.22%) and (29.50%) in probing depth, CAL gain and radiographic bone fill respectively.